NewEdge Advisors LLC Acquires 2,626 Shares of IQVIA Holdings Inc. $IQV

NewEdge Advisors LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,576 shares of the medical research company’s stock after purchasing an additional 2,626 shares during the period. NewEdge Advisors LLC’s holdings in IQVIA were worth $3,804,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in IQV. Nippon Life Global Investors Americas Inc. grew its stake in IQVIA by 9.3% in the first quarter. Nippon Life Global Investors Americas Inc. now owns 47,350 shares of the medical research company’s stock valued at $8,348,000 after acquiring an additional 4,020 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in IQVIA by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,282 shares of the medical research company’s stock valued at $8,865,000 after acquiring an additional 281 shares during the last quarter. Invenomic Capital Management LP grew its stake in shares of IQVIA by 65.7% during the 1st quarter. Invenomic Capital Management LP now owns 88,062 shares of the medical research company’s stock worth $15,525,000 after acquiring an additional 34,913 shares during the period. Hawk Ridge Capital Management LP purchased a new position in IQVIA in the 1st quarter valued at approximately $77,096,000. Finally, AQR Capital Management LLC grew its position in shares of IQVIA by 58.1% in the first quarter. AQR Capital Management LLC now owns 675,597 shares of the medical research company’s stock valued at $115,865,000 after purchasing an additional 248,353 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on IQV. Barclays increased their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. UBS Group upped their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Citigroup reissued a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Robert W. Baird raised their price target on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $229.64.

IQVIA Price Performance

Shares of IQV stock opened at $189.89 on Wednesday. The business’s 50 day moving average price is $181.03 and its 200-day moving average price is $167.36. The firm has a market cap of $32.28 billion, a P/E ratio of 27.48, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.